Ortho Clinical Diagnostics received the FDA approval of a diagnostic assay for the detection of antibodies to human immunodeficiency virus (HIV) types 1+2 (Anti-HIV 1+2) for use on the VITROS® 5600 Integrated and VITROS® 3600 Immunodiagnostic Systems. This is the first HIV diagnostic assay approved for an integrated system in the US, allowing laboratories to run HIV and other routine tests on a single testing platform and eliminating the need for expensive batch testing of multiple patient samples.

Stanbio Laboratory announced that the FDA has approved its HemoPoint H2 Hemoglobin Data Management System (DMS), which provides both a hemoglobin and calculated hematocrit result with one simple test. The new, HemoPoint H2 DMS utilizes connectivity to PCs via Bluetooth, control intervals and barcode identification of operators and patients to offer time-saving convenience, ease of data management technology and high quality control.

Asuragen, Inc. has announced that the Signature(R) LTx v2.0 Leukemia Translocation Panel was released as a “Conformite Europeenne” or “European Conformity” CE IVD product under the European Directive on In Vitro Diagnostic Medical Devices. The CE-marked Signature(R) LTx v2.0 is a qualitative in vitro diagnostic device for use in a clinical laboratory to identify specific fusion transcripts in total RNA from whole blood or bone marrow to aid in the clinical diagnosis of translocation positive leukemias. Clinical validation studies showed 100% diagnostic accuracy in comparison to standard cytogenetic methods. This represents the world’s first Luminex-based molecular oncology IVD product.

The U.S. Food and Drug Administration (FDA) has approved GE Healthcare’s molecular imaging agent AdreView™ (Iobenguane I 123 Injection) for the detection of rare neuroendocrine tumors in children and adults. The product provides images of high quality that assist physicians in the detection of tumors, at the initial stage as well as at the time when relapse is suspected. AdreView™ marks an advancement in diagnosis of cancer patients suffering from neuroblastoma. It will also identify primary and metastatic pheochromocytoma.

Pathway Diagnostics has released its patented, second-generation SensiTrop II assay for HIV-infected patients. The product combines the sensitivity of molecular heteroduplex tracking assay technology with molecular sequencing to determine the CCR5 co-receptor tropism status of patients, according to Pathway. It provides clinicians a fast, accurate, sensitive and economical testing alternative to biological HIV tropism assay.